Abstract

Case Report

Membranous nephropathy complicating relapsing polychondritis: A case report

Christopher Rice, Vatsalya Kosuru, John Jason White, Christine Van Beek, Rachel Elam*, Michael Clemenshaw, Laura Carbone and Leighton James

Published: 07 October, 2021 | Volume 5 - Issue 3 | Pages: 084-087

Background: Relapsing polychondritis is a rare systemic disease characterized by recurrent inflammation, and often destruction, of cartilaginous tissues. Renal manifestations are rare. Membranous nephropathy complicating relapsing polychondritis has been reported only once previously, and there is no standardized treatment for membranous nephropathy associated with relapsing polychondritis.
Case presentation: A 67-year-old Caucasian man with a history of chronic renal disease presented with 9 months of progressive dyspnea on exertion and 5 months of erythema, pain, and collapse of auricular cartilage. Imaging studies confirmed active inflammation of laryngeal, auricular, and costal cartilage and he was diagnosed with relapsing polychondritis.  Patient had longstanding proteinuria and renal biopsy demonstrated membranous nephropathy. Patient initially showed renal and respiratory improvement with etanercept, a tumor necrosis factor alpha inhibitor, treatment. However, subsequent disease and treatment-related complications led to a progressive overall clinical decline and patient died approximately 1 year following relapsing polychondritis diagnosis.
Conclusion: Membranous nephropathy may rarely complicate relapsing polychondritis. In our case, both the cartilaginous inflammation and the renal disease improved after treatment with tumor necrosis factor alpha blockade, however complications of existing airway disease led to recurrent hospitalizations and eventually death.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001080 Cite this Article Read Full Article PDF

Keywords:

Relapsing polychondritis; Membranous nephropathy; Systemic vasculitis; Tumor necrosis factor alpha inhibitor; Case report

References

  1. Gergely P Jr, Poór G. Relapsing polychondriti Best Pract Res Clin Rheumatol. 2004; 18: 723-738. PubMed: https://pubmed.ncbi.nlm.nih.gov/15454129/
  2. Chang-Miller A, Okamura M, Torres VE, Michet CJ, Wagoner RD, et al. Renal involvement in relapsing polychondriti Medicine. 1987; 66: 202-217. PubMed: https://pubmed.ncbi.nlm.nih.gov/3574118/
  3. Dalal BI, Wallace AC, Slinger RP. IgA nephropathy in relapsing polychondriti Pathology. 1988; 20: 85-89. PubMed: https://pubmed.ncbi.nlm.nih.gov/3287308/
  4. Meignan F, Maillefert F, Bargues L, Colle B, Colon S. Association of glomerular nephropathy with IgA deposits and relapsing polychondriti Ann Med Interne (Paris). 1992; 143: 548-550. PubMed: https://pubmed.ncbi.nlm.nih.gov/1303599/
  5. Borgia F, Giuffrida R, Guarneri F, Cannavò SP. Relapsing Polychondritis: An Updated Review. Biomedicine 2018; 6: 84. PubMed: https://pubmed.ncbi.nlm.nih.gov/30072598/
  6. Espinoza LR, Richman A, Bocanegra T, Pina I, Vasey FB, Rifkin SI, et al. Immune complex-mediated renal involvement in relapsing polychondriti Am J Med. 1981: 71; 181-183. PubMed: https://pubmed.ncbi.nlm.nih.gov/6454344/
  7. Lee JE, Lee EK. A case of membranous nephropathy associated with relapsing polychondritis. Kidney Res Clin Pract. 2012; 31: 253-256. PubMed: https://pubmed.ncbi.nlm.nih.gov/26894028/
  8. Churg J, Ehrenreich T. Membranous nephropathy. Perspect Nephrol Hypertens. 1973; 1: 443-448. PubMed: https://pubmed.ncbi.nlm.nih.gov/4536436/
  9. Moulis G, Sailler L, Pugnet G, Astudillo L, Arlet P. Biologics in relapsing polychondritis: a case seri Clin Exp Rheumatol. 2013; 31: 937-939. PubMed: https://pubmed.ncbi.nlm.nih.gov/24021708/
  10. Moulis G, Pugnet G, Costedoat-Chalumeau N, Mathian A, Leroux G, et al. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Ann Rheuma Di 2018; 77: 1172-1178. PubMed: https://pubmed.ncbi.nlm.nih.gov/29535124/
  11. Kaushik P, Rahmani M, Ellison W. Membranous glomerulonephritis with the use of etanercept in ankylosing spondyliti Ann Pharmacother. 2011; 45: e62. PubMed: https://pubmed.ncbi.nlm.nih.gov/22116994/
  12. Ammar A, Zafar Ahmed Mahmood H, Shahid Z, Jain R, Chen G. Etanercept-associated Nephropathy. Cureu 2019; 11: e5419. PubMed: https://pubmed.ncbi.nlm.nih.gov/31632872/
  13. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthriti Nephrol Dial Transplant. 2005; 20: 1400-1406. PubMed: https://pubmed.ncbi.nlm.nih.gov/15840673/
  14. Cantarini L, Vitale A, Brizi MG, Caso F, Frediani B, et al. Diagnosis and classification of relapsing polychondritis. J Autoimmun. 2014; 48-49: 53-59. PubMed: https://pubmed.ncbi.nlm.nih.gov/24461536/
  15. Yamada T, Itagaki F, Aratani S, Kawasaki S, Terada K, et al. A case of membranous nephropathy diagnosed with lupus nephritis 11 years after onset. CEN Case Rep. 2019; 8: 301-307. PubMed: https://pubmed.ncbi.nlm.nih.gov/31399881/
  16. Santoro D, Postorino A, Costantino G, Savica V, Bellinghieri G. Anti-TNF-alpha therapy in membranous glomerulonephritis. Clin Kidney J. 2012; 5: 487-488. PubMed: https://pubmed.ncbi.nlm.nih.gov/26019836/

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More